Price movement over the last 24 hours
ADMA Biologics Inc vs EHang Holdings Ltd - ADR — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while EHang Holdings Ltd - ADR trades at $5.42 (market cap $417.53M). The key difference: ADMA Biologics Inc is far larger — about 5.1× EHang Holdings Ltd - ADR's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| ADMA | EH | |
|---|---|---|
Market Cap | $2.13B | $417.53M |
Sector | Health | Industrials |
52-Week High | $20.38 | $19.99 |
52-Week Low | $7.60 | $5.52 |
Enterprise Value | $2.20B | $357.19M |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
EHang Holdings trades at $5.52, down 12.52% over 24 hours, reflecting bearish technical signals and weak quarterly earnings. The company reported a net loss of $275.98 million for 2025 with a -77.56% net margin, though revenue reached $417.98 million. Recent news highlights volatility, including an 18% surge on June 15, 2026, following a Q1 2026 earnings miss reported by The Motley Fool on June 9, 2026.
The outlook remains challenged by persistent losses and high cash burn, but analyst consensus suggests moderate upside with a $7.75 price target. Key risks include execution delays in eVTOL commercialization and reliance on financing amid negative cash flows, while institutional sentiment is mixed with 40% buy ratings.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →